Latest Updates

Promotions
Promotions
New Data
New Data
Lab Schedule
Lab Schedule
Bug Fixes
Bug Fixes
Updates
Updates
New Features
New Features
Updates
September 16, 2023

⚠️Urgent: Recent Heatwave Precautions for Submitting Your ImpriMed Samples

As you may be aware, a significant heatwave is currently affecting various regions across the United States. In light of these challenging conditions, we kindly request your attention to the following important shipping instructions.

Read More →
Updates
September 16, 2023

Support oncology research by sending latest medical records

We really appreciate you and your patients for being awesome ImpriMed users! If you've ordered the ImpriMed Personalized Prediction Profile, you can expect an email from us in about 3-4 months. We'll be asking for updated patient medical records to help us make our service even better

Read More →
Updates
September 16, 2023

ImpriMed Launches Multidrug Sensitivity Genotyping (MDR1) for Dogs

We are thrilled to announce that our Multidrug Sensitivity Genotyping (MDR1) is now available to provide you actionable information about the sensitivity of your canine patients to many commonly-used drugs.

Read More →
Updates
September 16, 2023

Dexamethasone and Mechlorethamine are now included in the AI-driven Single Drug Response Models

Thanks to your contributions in providing post-ImpriMed patient medical records, we used machine learning (ML) to develop single drug response models for Dexamethasone and Mechlorethamine.

Read More →
Updates
September 16, 2023

Announcing ImpriMed’s Next Generation of AI Models for CHOP Therapy Outcome Prediction (v2)

ImpriMed is thrilled to announce that, on November 1st 2022, we will be upgrading the CHOP therapy section of our Personalized Prediction Profile with more powerful artificial intelligence (AI) models and an easy-to-read report format that provides faster access to critical information.

Read More →
Updates
September 16, 2023

ImpriMed releases a new generation of artificial intelligence models

On June 27th, ImpriMed's Data Science team released a new generation of AI models for canine lymphoma with improved predictive performance. The models, which predict the likelihood of a positive clinical response to 10 different chemotherapy drugs, were optimized to give higher sensitivity and...

Read More →